Why the study?
Although an association between atrial high-rate episodes and stroke has been reported, data for the Asian population are limited.
Does longer atrial high-rate episode (AHRE) burden increase the risk of ischemic and major bleeding events in patients with a cardiac implantable electronic device?
Does longer atrial high-rate episode (AHRE) burden increase the risk of ischemic and major bleeding events in patients with a cardiac implantable electronic device?
In patients with cardiac implantable electronic devices, an atrial high-rate episode burden of ≥24 hours is associated with increased risks of both ischemic and major bleeding events, emphasizing the need for careful bleeding risk assessment when considering anticoagulation.
High AHRE burden linked to more ischemic/bleeding events in CIED patients; leaves open independent role of duration beyond age ≥85.
BACKGROUND: An association between atrial high-rate episode (AHRE) and stroke has been reported, although data for the Asian population are limited. This study aimed to investigate the role of AHRE in ischemic and major bleeding events in patients who underwent a cardiac implantable electronic device (CIED) procedure. METHODS AND RESULTS: This single-center historical cohort study included 710 patients (age: 78±11 years, 374 women) who underwent a CIED-related procedure between October 2009 and September 2019 at Shimane Prefectural Central Hospital (median follow-up period: 4.5 [2.5, 7] years, 3439 person-years). Based on the maximum AHRE burden, patients were divided into: (1) <6 min; (2) ≥6 min to 24-h; and (3) ≥24-h groups. The cumulative incidence of ischemic (ischemic stroke, systemic embolism, and transient ischemic attack) and major bleeding (≥3 Bleeding Academic Research Consortium bleeding criteria) events after the procedure were compared. Uni- and multivariate analyses were performed to identify factors associated with these events. The incidence of both events increased with the rising AHRE burden, being significantly higher in the ≥24-h group than in the <6 min group. Multivariate analysis found age ≥85 years to be the only independent factor associated with both events. CONCLUSIONS: Longer AHRE duration is associated with a high number of major bleeding and ischemic events. Monitoring these bleeding risks is mandatory when clinicians are considering anticoagulation therapy for such patients.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: